CN110072865A - 吡咯并芳杂环类化合物及其制备方法和医药用途 - Google Patents

吡咯并芳杂环类化合物及其制备方法和医药用途 Download PDF

Info

Publication number
CN110072865A
CN110072865A CN201780076186.0A CN201780076186A CN110072865A CN 110072865 A CN110072865 A CN 110072865A CN 201780076186 A CN201780076186 A CN 201780076186A CN 110072865 A CN110072865 A CN 110072865A
Authority
CN
China
Prior art keywords
phenyl
alkyl
pyrrolo
pyrimidine
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780076186.0A
Other languages
English (en)
Other versions
CN110072865B (zh
Inventor
殷惠军
闫旭
宗利斌
田卫学
郑礼
窦浩帅
杨琰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Pharmaceutical R&D Co Ltd
Original Assignee
National Institutes of Pharmaceutical R&D Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Pharmaceutical R&D Co Ltd filed Critical National Institutes of Pharmaceutical R&D Co Ltd
Publication of CN110072865A publication Critical patent/CN110072865A/zh
Application granted granted Critical
Publication of CN110072865B publication Critical patent/CN110072865B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明涉及吡咯并芳杂环类化合物及其制备方法和医药用途。特别地，本发明涉及通式I所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为BTK激酶抑制剂的用途，该化合物及其含有该化合物的药物组合物可以用于治疗与BTK激酶活性相关的疾病，例如炎症、自身免疫性病症、癌症等。其中通式I中的各取代基的定义与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201780076186.0A 2017-02-08 2017-12-26 吡咯并芳杂环类化合物及其制备方法和医药用途 Active CN110072865B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017100687987 2017-02-08
CN201710068798 2017-02-08
PCT/CN2017/118424 WO2018145525A1 (zh) 2017-02-08 2017-12-26 吡咯并芳杂环类化合物及其制备方法和医药用途

Publications (2)

Publication Number Publication Date
CN110072865A true CN110072865A (zh) 2019-07-30
CN110072865B CN110072865B (zh) 2022-02-11

Family

ID=63107868

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780076186.0A Active CN110072865B (zh) 2017-02-08 2017-12-26 吡咯并芳杂环类化合物及其制备方法和医药用途

Country Status (5)

Country Link
US (1) US11608334B2 (zh)
EP (1) EP3556761B1 (zh)
JP (1) JP7164203B2 (zh)
CN (1) CN110072865B (zh)
WO (1) WO2018145525A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021037188A1 (zh) * 2019-08-29 2021-03-04 中国科学院上海药物研究所 嘧啶并[5,4-b]吡呤化合物的制药用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN112812117B (zh) * 2019-11-18 2023-12-22 中国医药研究开发中心有限公司 一种btk抑制剂的新晶型及其制备方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004833A2 (en) * 2004-06-28 2006-01-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2013157021A1 (en) * 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
CN103732596A (zh) * 2011-07-08 2014-04-16 诺华股份有限公司 新的吡咯并嘧啶衍生物
CN103748096A (zh) * 2012-08-06 2014-04-23 美国艾森生物科学公司 作为蛋白激酶抑制剂的新型吡咯并嘧啶化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054279A1 (en) 2008-11-10 2010-05-14 Schering Corporation Compounds for the treatment of inflammatory disorders
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
TWI516262B (zh) 2010-04-06 2016-01-11 健康網路大學 激酶抑制劑及以其治療癌症的方法
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
EP2766352B1 (en) 2011-10-12 2018-06-06 University Health Network (UHN) Indazole compounds as kinase inhibitors and method of treating cancer with same
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
KR102173433B1 (ko) 2013-07-11 2020-11-04 에이시아 바이오사이언시스 인코포레이티드. 키나아제 억제제로써의 피리미딘 유도체
EP3080122B1 (en) 2013-12-11 2018-10-31 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2016004305A2 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
KR101692510B1 (ko) * 2015-06-16 2017-01-03 엘지이노텍 주식회사 내구성 향상을 위한 무선충전장치
KR20180051220A (ko) * 2016-11-08 2018-05-16 주식회사 대웅제약 신규한 피롤로피리미딘 유도체 및 이를 포함하는 약학적 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004833A2 (en) * 2004-06-28 2006-01-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN103732596A (zh) * 2011-07-08 2014-04-16 诺华股份有限公司 新的吡咯并嘧啶衍生物
WO2013157021A1 (en) * 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
CN103748096A (zh) * 2012-08-06 2014-04-23 美国艾森生物科学公司 作为蛋白激酶抑制剂的新型吡咯并嘧啶化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021037188A1 (zh) * 2019-08-29 2021-03-04 中国科学院上海药物研究所 嘧啶并[5,4-b]吡呤化合物的制药用途

Also Published As

Publication number Publication date
US20200062749A1 (en) 2020-02-27
EP3556761A4 (en) 2019-12-25
US11608334B2 (en) 2023-03-21
JP2020509999A (ja) 2020-04-02
CN110072865B (zh) 2022-02-11
WO2018145525A1 (zh) 2018-08-16
JP7164203B2 (ja) 2022-11-01
EP3556761B1 (en) 2021-03-03
EP3556761A1 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
CN110072865A (zh) 吡咯并芳杂环类化合物及其制备方法和医药用途
CN105524048B (zh) 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用
CN107759587B (zh) [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CN103420977A (zh) 具有抗肿瘤活性的乙炔衍生物
BRPI0718803A2 (pt) Composto para inibir a progressão mitótica
CN103038233A (zh) 吡啶酮和氮杂吡啶酮化合物及使用方法
CN107531679A (zh) 芳香酰胺类衍生物、其制备方法及其在医药上的应用
JP7077323B2 (ja) キナゾリン化合物並びにその調製方法、使用及び医薬組成物
EP3845527A1 (en) Multi-substituted pyridone derivatives and medical use thereof
CN110167941A (zh) 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
CN114423760A (zh) 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN115594695A (zh) 大环类化合物、其制备方法及其在医药上的应用
CN112300173A (zh) 一类含氮多环类化合物、制备方法和用途
WO2023036252A1 (zh) 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
CN111153891A (zh) 一种取代苯并咪唑类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
CN115785154A (zh) 杂芳环化合物及其医药用途
CN115772161A (zh) 含氮杂芳基化合物、其制备方法及其在医药上的应用
CN105541792B (zh) 多环类pi3k抑制剂
CN107880038A (zh) [1,2,4]三唑并[1,5‑a]吡啶类化合物及其制备方法和医药用途
CN109206435A (zh) 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途
WO2020156505A1 (zh) 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用
CN113087709A (zh) 吡咯并嘧啶类衍生物及其制备方法和应用
TW202140474A (zh) 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用
CN117865939A (zh) 氨基嘧啶类衍生物抑制剂、其制备方法和应用
WO2022161447A1 (zh) 二甲酰胺类化合物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40005575

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant